文献速递甲状腺疾病肥胖与代谢综合征

非酒精性脂肪肝与高胆固醇血症:甲状腺激素、代谢物及激动剂的作用

Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists.
PubMed 文献 · Thyroid · 2019-01-01

综述阐述甲状腺激素(TH)在全身和肝脏水平调控脂蛋白、甘油三酯及胆固醇代谢,从而影响非酒精性脂肪肝(NAFLD)和高胆固醇血症的发病。TH受体β类似物、TH代谢物T2和T1AM以及靶向肝脏的前药和偶联物正在研究中,TH疗法对NAFLD和高胆固醇血症有临床前景,但需监测肝脏特异性TH作用标志物以评估疗效和剂量。

要点

  • TH调控肝脏甘油三酯和胆固醇代谢,降低血清胆固醇和肝内脂质含量。
  • TH受体β类似物正在NAFLD和高胆固醇血症的II期临床研究中测试。
  • TH代谢物T2和T1AM对脂代谢的作用与T3不同,临床应用仍在研究中。

核心结论

  • 基于TH的疗法对治疗NAFLD和高胆固醇血症显示出临床前景。
  • 限制TH副作用的策略正在开发,可能使TH代谢物和类似物在肝脏发挥特异性作用。

研究设计与样本

  • 综述,未报告系统检索范围。

主要发现

  • TH通过调控肝脏TAG和胆固醇代谢的多个过程,降低血清胆固醇和肝内脂质含量。
  • TH受体β类似物设计为副作用少于天然激素,正在NAFLD和高胆固醇血症的II期临床研究中测试。
  • TH代谢物T2和T1AM对脂代谢的有益作用与T3不同,但临床应用仍在研究中。
  • 已开发前药和胰高血糖素/T3偶联物,可将TH导向肝脏。

临床怎么用

  • TH疗法有望用于NAFLD和高胆固醇血症,但需监测肝脏特异性TH作用标志物以评估临床疗效和给药剂量。
  • 需关注肝脏特异性效应及对下丘脑/垂体/甲状腺轴的潜在抑制。

局限性

  • TH代谢物T2和T1AM的临床应用仍在研究中。
  • TH类似物限制副作用的策略仍在开发中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Thyroid hormones (THs) exert a strong influence on mammalian lipid metabolism at the systemic and hepatic levels by virtue of their roles in regulating circulating lipoprotein, triglyceride (TAG), and cholesterol levels, as well as hepatic TAG storage and metabolism. These effects are mediated by intricate sensing and feedback systems that function at the physiological, metabolic, molecular, and transcriptional levels in the liver. Dysfunction in the pathways involved in lipid metabolism disrupts hepatic lipid homeostasis and contributes to the pathogenesis of metabolic diseases, such as nonalcoholic fatty liver disease (NAFLD) and hypercholesterolemia. There has been strong interest in understanding and employing THs, TH metabolites, and TH mimetics as lipid-modifying drugs. Summary: THs regulate many processes involved in hepatic TAG and cholesterol metabolism to decrease serum cholesterol and intrahepatic lipid content. TH receptor β analogs designed to have less side effects than the natural hormone are currently being tested in phase II clinical studies for NAFLD and hypercholesterolemia. The TH metabolites, 3,5-diiodo-l-thyronine (T2) and T1AM (3-iodothyronamine), have different beneficial effects on lipid metabolism compared with triiodothyronine (T3), although their clinical application is still under investigation. Also, prodrugs and glucagon/T3 conjugates have been developed that direct TH to the liver. Conclusions: TH-based therapies show clinical promise for the treatment of NAFLD and hypercholesterolemia. Strategies for limiting side effects of TH are being developed and may enable TH metabolites and analogs to have specific effects in the liver for treatments of these conditions. These liver-specific effects and potential suppression of the hypothalamic/pituitary/thyroid axis raise the issue of monitoring liver-specific markers of TH action to assess clinical efficacy and dosing of these compounds.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Sinha RA, Bruinstroop E, Singh BK, et al. Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists. Thyroid. 2019. PMID: 31389309. doi:10.1089/thy.2018.0664

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。